Journal article · 2022 · Open access

Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo

Huanzhen Ni, Marine Z. C. Hatit, Kun Zhao, David Loughrey, Melissa P. Lokugamage, Hannah E. Peck, Ada Del Cid, Abinaya Muralidharan, YongTae Kim, Philip J. Santangelo, James E. Dahlman

Nature Communications, 13(1), 4766 · Published 15 August 2022 · DOI 10.1038/s41467-022-32281-5

Open PDFView at the publisherCite this paper

In brief

“Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo” is a 2022 journal article by Huanzhen Ni and 10 co-authors, published in Nature Communications. OpenAlex counts 208 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Nature Communications.

Citations
208
Most cited in
2025 (61)
Field-weighted impact
10.36
References
53
Authors
11

Abstract

In humans, lipid nanoparticles (LNPs) have safely delivered therapeutic RNA to hepatocytes after systemic administration and to antigen-presenting cells after intramuscular injection. However, systemic RNA delivery to non-hepatocytes remains challenging, especially without targeting ligands such as antibodies, peptides, or aptamers. Here we report that piperazine-containing ionizable lipids (Pi-Lipids) preferentially deliver mRNA to immune cells in vivo without targeting ligands. After synthesizing and characterizing Pi-Lipids, we use high-throughput DNA barcoding to quantify how 65 chemically distinct LNPs functionally delivered mRNA (i.e., mRNA translated into functional, gene-editing protein) in 14 cell types directly in vivo. By analyzing the relationships between lipid structure and cellular targeting, we identify lipid traits that increase delivery in vivo. In addition, we characterize Pi-A10, an LNP that preferentially delivers mRNA to the liver and splenic immune cells at the clinically relevant dose of 0.3 mg/kg. These data demonstrate that high-throughput in vivo studies can identify nanoparticles with natural non-hepatocyte tropism and support the hypothesis that lipids with bioactive small-molecule motifs can deliver mRNA in vivo.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ni, H., Hatit, M. Z. C., Zhao, K., Loughrey, D., Lokugamage, M. P., Peck, H. E., Del Cid, A., Muralidharan, A., Kim, Y., Santangelo, P. J., & Dahlman, J. E. (2022). Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nature Communications, 13(1), 4766. https://doi.org/10.1038/s41467-022-32281-5

MLA 9

Ni, Huanzhen, et al. “Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo.” Nature Communications, vol. 13, no. 1, 2022, p. 4766. https://doi.org/10.1038/s41467-022-32281-5.

Chicago

Ni, Huanzhen, Marine Z. C. Hatit, Kun Zhao, David Loughrey, Melissa P. Lokugamage, Hannah E. Peck, Ada Del Cid, et al. 2022. “Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo.” Nature Communications 13 (1): 4766. https://doi.org/10.1038/s41467-022-32281-5.

Harvard

Ni, H. et al. (2022) ‘Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo’, Nature Communications, 13(1), p. 4766. doi:10.1038/s41467-022-32281-5.

IEEE

H. Ni et al., “Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo,” Nature Communications, vol. 13, no. 1, p. 4766, 2022, doi: 10.1038/s41467-022-32281-5.

BibTeX

@article{ni2022piperazine,
  title     = {{Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo}},
  author    = {Ni, Huanzhen and Hatit, Marine Z. C. and Zhao, Kun and Loughrey, David and Lokugamage, Melissa P. and Peck, Hannah E. and Del Cid, Ada and Muralidharan, Abinaya and Kim, YongTae and Santangelo, Philip J. and Dahlman, James E.},
  journal   = {Nature Communications},
  year      = {2022},
  volume    = {13},
  number    = {1},
  pages     = {4766},
  doi       = {10.1038/s41467-022-32281-5},
  url       = {https://doi.org/10.1038/s41467-022-32281-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202211
20233535
20245555
20256161
20265656

Its field-weighted citation impact is 10.36: it has been cited 10.36 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery

  • lipid nanoparticles
  • mRNA delivery
  • immune cells
  • splenic B cells
  • liver targeting
  • DNA barcoding
  • in vivo delivery
  • genome editing

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Ni, H., Hatit, M. Z. C., Zhao, K., Loughrey, D., Lokugamage, M. P., Peck, H. E., Del Cid, A., Muralidharan, A., Kim, Y., Santangelo, P. J., & Dahlman, J. E. (2022). Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nature Communications, 13(1), 4766. https://doi.org/10.1038/s41467-022-32281-5

How many times has this paper been cited?

208 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Communications: sign in and open the PDF from this page.

Who wrote this paper?

Huanzhen Ni, Marine Z. C. Hatit, Kun Zhao, David Loughrey, Melissa P. Lokugamage, Hannah E. Peck, Ada Del Cid, Abinaya Muralidharan, YongTae Kim, Philip J. Santangelo, James E. Dahlman.

What is the DOI of this paper?

10.1038/s41467-022-32281-5, permanently at https://doi.org/10.1038/s41467-022-32281-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.